Potential interactions between iloprost and SIN-1 on platelet aggregation and myocardial infarct size in vivo

European Journal of Pharmacology

Volumn 374, Issue 1, 1999, Pages 59-69

  Aitchison, Keri A ^a   Coker, Susan J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Iloprost; Myocardial infarction; Nitric oxide (NO) donor; Platelet aggregation; Prostacyclin; SIN 1 (3 morpholino sydnonimine)

Indexed keywords

ADENOSINE DIPHOSPHATE; COLLAGEN; ILOPROST; LINSIDOMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; THROMBOCYTE AGGREGATION;

ANIMALS; ARRHYTHMIA; CREATINE KINASE; DRUG SYNERGISM; ELECTROCARDIOGRAPHY; HEMODYNAMIC PROCESSES; ILOPROST; MALE; MOLSIDOMINE; MYOCARDIAL INFARCTION; PLATELET AGGREGATION; RABBITS;

EID: 0033028269     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00289-7     Document Type: Article

References (37)

1. Aitchison, K.A., 1996. Interactions among nitric oxide, prostacyclin and platelets in myocardial ischaemia. PhD Thesis, The University of Liverpool.
2. Aitchison K.A., Coker S.J. Effects of SIN-1 and iloprost, alone and in combination, on myocardial infarct size in anaesthetized rabbits. Br. J. Pharmacol. 117:1996;54P.
3. Badimon L., Badimon J.J., Penny W., Webster M.W., Chesebro J.H., Fuster V. Endothelium and atherosclerosis. J. Hypertens. 10:1992;S43-S50.
4. 111In -labeled platelet accumulation in infarcted myocardium J. Cardiovasc. Pharmacol. 7:1985;906-912.
5. Bieron K., Grodzinska L., Kostka-Trabka E., Gryglewski R.J. Prostacyclin and molsidomine synergise in their fibrinolytic and antiplatelet actions in patients with peripheral arterial disease. Wien. Klin. Wochenschr. 105:1993;7-11.
6. Chiariello M., Golino P., Cappelli-Bigazzi M., Ambrosio G., Tritto I., Salvatore M. Reduction in infarct size by the prostacyclin analogue iloprost (ZK36374) after experimental coronary artery occlusion-reperfusion. Am. Heart J. 115:1988;499-504.
7. Coker S.J. Anesthetized rabbit as a model for ischemia- and reperfusion-induced arrhythmias. J. Pharmacol. Methods. 21:1989;263-279.
8. 2α, prostacyclin, flurbiprofen and aspirin on arrhythmias resulting from coronary artery ligation in anaesthetized rats. Br. J. Pharmacol. 74:1981;155-159.
9. Coker S.J., Parratt J.R. Prostacyclin - antiarrhythmic or arrhythmogenic? Comparison of the effects of intravenous and intracoronary prostacyclin and ZK36374 during coronary artery occlusion and reperfusion in anaesthetised greyhounds. J. Cardiovasc. Pharmacol. 5:1983;557-567.
10. Curtis M.J., Pabla R. Nitric oxide supplementation or synthesis block - which is the better approach to treatment of heart disease? Trends Pharmacol. Sci. 18:1997;239-244.
11. Feelisch M. The use of nitric oxide donors in pharmacological studies. Naunyn-Schmeideberg's Arch. Pharmacol. 358:1998;113-122.
12. Flores N.A. Platelet activation during myocardial ischaemia: a contributory arrhythmogenic mechanism. Pharmacol. Ther. 72:1996;1-26.
13. Flores N.A., Seghatchian M.J., Sheridan D.J. Platelet-mediated alterations during myocardial ischaemia. Blood Coagulation Fibrinolysis. 2:1991;367-371.
14. Fung K.-P., Wu T.-W., Zeng L.-H., Wu J. The opposing effects of an inhibitor of nitric oxide synthesis and a donor of nitric oxide in rabbits undergoing myocardial ischemia reperfusion. Life Sci. 54:1994;491-496.
15. Gryglewski R.J., Korbut R., Trabka-Janik E., Zembowicz A., Trybulec M. Interaction between NO donors and iloprost in human vascular smooth muscle, platelets and leukocytes. J. Cardiovasc. Pharmacol. 14:1989;S124-S128.
16. Johnson G., Tsao P.S., Lefer A.M. Cardioprotective effects of authentic nitric oxide in myocardial ischemia with reperfusion. Crit. Care Med. 19:1991;244-252.
17. Kita Y., Sugimoto T., Hirasawa Y., Yoshida K., Maeda K. Close correlation of the cardioprotective effects of FK409, a spontaneous NO releaser, with an increase in plasma cyclic GMP level. Br. J. Pharmacol. 113:1994;5-6.
18. Laws H.K., Clanton J.A., Stanres V.A., Lupinetti L.M., Collins J.C., Oates J.A., Hammon J.W. Jr. Kinetics and imaging of indium-111-labeled autologous platelets in experimental myocardial infarction. Circulation. 67:1983;110-116.
19. Liu G.-L., Christopher T.A., Lopez B.L., Gao F., Guo Y., Gao E., Knuettel K., Feelisch M., Ma X.L. SP/W-5186, a cysteine-containing nitric oxide donor, attenuates postischemic myocardial injury. J. Pharmacol. Exp. Ther. 287:1998;527-537.
20. Ma X.L., Lopez B.L., Liu G.-L., Christopher T.A., Ischiropoulos H. Peroxynitrite aggravates myocardial reperfusion injury in the isolated perfused rat heart. Cardiovasc. Res. 36:1997;195-204.
21. Macdonald P.S., Read M.A., Dusting G.J. Synergistic inhibition of platelet aggregation by endothelium derived relaxing factor and prostacyclin. Thromb. Res. 49:1988;437-449.
22. Martorana P.A., Kettenbach B., Bohn H., Schonafinger K., Henning R. Antiischemic effects of pirsidomine, a new nitric oxide donor. Eur. J. Pharmacol. 257:1994;267-273.
23. Mullane K.M., Fornabaio D. Thromboxane synthetase inhibitors reduce infarct size by a platelet-dependent, aspirin-sensitive mechanism. Circ. Res. 62:1985;668-678.
24. Müller, B., Maaß, B., Sturzebecher, S., Witt, W., 1987. Effects of iloprost on arrhythmias and infarct size in rats after coronary artery ligation. In: Gryglewski, R.J., Stock, G. (Eds.), Prostacyclin and its Stable Analogue Iloprost. Springer-Verlag, Berlin, pp. 195-204.
25. Nash G.B. Adhesion between neutrophils and platelets: a modulator of thrombotic and inflammatory events. Thromb. Res. 74(1):1994;S3-S11. Suppl.
26. Nossuli T.O., Hayward R., Scalia R., Lefer A.M. Peroxynitrite reduces myocardial infarct size and preserves coronary endothelium after ischemia and reperfusion in cats. Circulation. 96:1997;2317-2324.
27. Radomski M.W., Palmer R.M.J., Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br. J. Pharmacol. 92:1987;181-187.
28. Schlack W., Uebing A., Schäfer M., Bier F., Grunert S., Ebel D., Piper H.M., Thämer V. Intracoronary SIN-1C during reperfusion reduces infarct size in dog. J. Cardiovasc. Pharmacol. 25:1995;424-431.
29. 2 antagonists. Br. J. Pharmacol. 117:1996;817-822.
30. 2 and thromboxane antagonists: effects on platelet aggregation and isolated cardiac muscle. Br. J. Pharmacol. 121:1997;875-882.
31. Siegfried M.R., Erhardt J., Rider T., Ma X.L., Lefer A.M. Cardioprotection and attenuation of endothelial dysfunction by organic nitric oxide donors in myocardial ischemia-reperfusion. J. Pharmacol. Exp. Ther. 260:1992;668-675.
32. Simpson P.J., Fantone J.C., Mickelson J.K., Gallagher K.P., Lucchesi B.R. Identification of a time window for therapy to reduce experimental canine myocardial injury: suppression of neutrophil activation during 72 h of reperfusion. Circ. Res. 63:1988;1070-1079.
33. Tsao P.S., Lefer A.M. Time course and mechanism of endothelial dysfunction in isolated ischemic- and hypoxic-perfused rat hearts. Am. J. Physiol. 259:1990;H1660-H1666.
34. Van Benthuysen K.M., McMurtry I.F., Horowitz L.D. Reperfusion after acute coronary occlusion in dogs impairs endothelium-dependent relaxation to acetylcholine and augments contractile activity in vitro. J. Clin. Invest. 79:1987;265-274.
35. Wainwright C.L., Parratt J.R., Bigaud M. The effects of PAF antagonists on arrhythmias and platelets during acute myocardial ischaemia and reperfusion. Eur. Heart J. 10:1989;235-243.
36. Walker M.J.A., Curtis M.J., Hearse D.J., Campbell R.N.F., Janse M.J., Yellon D.M., Cobbe S.M., Coker S.J., Harness J.B., Harron D.W.G., Higgins A.J., Julian D.G., Lab M.J., Manning A.S., Northover B.J., Parratt J.R., Riemersma R.A., Riva E., Russell D.C., Sheridan D.J., Winslow P., Woodward B. The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia, infarction and reperfusion. Cardiovasc. Res. 22:1988;447-455.
37. Yasmin W., Strynadka K.D., Schulz R. Generation of peroxynitrite contributes to ischemia-reperfusion injury in isolated rat hearts. Cardiovasc. Res. 33:1997;422-432.